A gush of $100 million funding for “Superblood” startup
Mar 10, 2018, 4:51 AM EST
(Source: Andrew Mason/flickr)
Rubius Therapeutics, a biotech startup, is developing genetically engineered red blood cells that can be loaded up with therapeutic proteins and transfused in patients battling cancer and other rare conditions.
The company recently raised $100 million in funding in addition to $120 million bagged previously within last one year, which is testament to investors’ confidence in the startup’s idea of “superblood,” writes Digital Trends.
Such re-engineering of the body’s immune system eliminates the need for personalized treatments like the current cell therapies involved, notes Business Insider.
